ES2708655T3 - Métodos para tratar el rechazo mediado por anticuerpos en pacientes con trasplante de órganos con el inhibidor de la c1-esterasa - Google Patents
Métodos para tratar el rechazo mediado por anticuerpos en pacientes con trasplante de órganos con el inhibidor de la c1-esterasa Download PDFInfo
- Publication number
- ES2708655T3 ES2708655T3 ES14809567T ES14809567T ES2708655T3 ES 2708655 T3 ES2708655 T3 ES 2708655T3 ES 14809567 T ES14809567 T ES 14809567T ES 14809567 T ES14809567 T ES 14809567T ES 2708655 T3 ES2708655 T3 ES 2708655T3
- Authority
- ES
- Spain
- Prior art keywords
- inh
- patients
- amr
- treatment
- days
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229940009550 c1 esterase inhibitor Drugs 0.000 title claims abstract description 156
- 206010052779 Transplant rejections Diseases 0.000 title claims abstract description 103
- 210000000056 organ Anatomy 0.000 title claims abstract description 69
- 238000000034 method Methods 0.000 title claims abstract description 56
- 238000002054 transplantation Methods 0.000 title claims description 41
- 102000055157 Complement C1 Inhibitor Human genes 0.000 claims abstract description 146
- 108050007539 Plasma protease C1 inhibitor Proteins 0.000 claims abstract description 142
- 238000001990 intravenous administration Methods 0.000 claims abstract description 30
- 238000011282 treatment Methods 0.000 claims description 95
- 238000002616 plasmapheresis Methods 0.000 claims description 53
- 210000003734 kidney Anatomy 0.000 claims description 43
- 238000002560 therapeutic procedure Methods 0.000 claims description 34
- 108060003951 Immunoglobulin Proteins 0.000 claims description 24
- 102000018358 immunoglobulin Human genes 0.000 claims description 24
- 210000002381 plasma Anatomy 0.000 claims description 18
- 230000001225 therapeutic effect Effects 0.000 claims description 16
- 230000001684 chronic effect Effects 0.000 claims description 12
- 229960004641 rituximab Drugs 0.000 claims description 11
- 208000022461 Glomerular disease Diseases 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 229960002224 eculizumab Drugs 0.000 claims description 9
- 239000007787 solid Substances 0.000 claims description 9
- 229960001467 bortezomib Drugs 0.000 claims description 8
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 8
- 239000004023 fresh frozen plasma Substances 0.000 claims description 7
- 210000004698 lymphocyte Anatomy 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 238000003745 diagnosis Methods 0.000 claims description 5
- 206010063209 Chronic allograft nephropathy Diseases 0.000 claims description 4
- 210000002216 heart Anatomy 0.000 claims description 4
- 210000000936 intestine Anatomy 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 4
- 210000000496 pancreas Anatomy 0.000 claims description 4
- 230000002829 reductive effect Effects 0.000 claims description 4
- 210000004185 liver Anatomy 0.000 claims description 2
- 101001081555 Homo sapiens Plasma protease C1 inhibitor Proteins 0.000 description 62
- 229940088949 cinryze Drugs 0.000 description 60
- 102000044507 human SERPING1 Human genes 0.000 description 60
- 229940068196 placebo Drugs 0.000 description 43
- 239000000902 placebo Substances 0.000 description 43
- 239000000203 mixture Substances 0.000 description 38
- 230000000295 complement effect Effects 0.000 description 21
- 230000000694 effects Effects 0.000 description 21
- 230000001154 acute effect Effects 0.000 description 20
- 239000000427 antigen Substances 0.000 description 19
- 108091007433 antigens Proteins 0.000 description 19
- 102000036639 antigens Human genes 0.000 description 19
- 239000013543 active substance Substances 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 14
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 14
- 238000001574 biopsy Methods 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- 238000001802 infusion Methods 0.000 description 13
- 230000007423 decrease Effects 0.000 description 12
- 230000024203 complement activation Effects 0.000 description 11
- 230000003907 kidney function Effects 0.000 description 11
- 239000008194 pharmaceutical composition Substances 0.000 description 11
- 230000004083 survival effect Effects 0.000 description 11
- 230000007774 longterm Effects 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 230000004154 complement system Effects 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 210000005084 renal tissue Anatomy 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 230000036470 plasma concentration Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 229940109239 creatinine Drugs 0.000 description 7
- 230000037361 pathway Effects 0.000 description 7
- 238000011272 standard treatment Methods 0.000 description 7
- 230000000890 antigenic effect Effects 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 6
- 208000020832 chronic kidney disease Diseases 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 201000000523 end stage renal failure Diseases 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 206010019860 Hereditary angioedema Diseases 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000015271 coagulation Effects 0.000 description 5
- 238000005345 coagulation Methods 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 238000000586 desensitisation Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 230000003285 pharmacodynamic effect Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 108700040183 Complement C1 Inhibitor Proteins 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000002408 directed self-assembly Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 238000001493 electron microscopy Methods 0.000 description 4
- 208000028208 end stage renal disease Diseases 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 238000002689 xenotransplantation Methods 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 108090001090 Lectins Proteins 0.000 description 3
- 102000004856 Lectins Human genes 0.000 description 3
- 102000009112 Mannose-Binding Lectin Human genes 0.000 description 3
- 108010087870 Mannose-Binding Lectin Proteins 0.000 description 3
- 241000282520 Papio Species 0.000 description 3
- 206010070834 Sensitisation Diseases 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 238000011316 allogeneic transplantation Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000000635 electron micrograph Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000004761 fibrosis Effects 0.000 description 3
- 230000002427 irreversible effect Effects 0.000 description 3
- 239000002523 lectin Substances 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 229920005862 polyol Polymers 0.000 description 3
- 150000003077 polyols Chemical class 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000008313 sensitization Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 230000008719 thickening Effects 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- 230000002747 voluntary effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 102000000989 Complement System Proteins Human genes 0.000 description 2
- 108010069112 Complement System Proteins Proteins 0.000 description 2
- 229940124073 Complement inhibitor Drugs 0.000 description 2
- 229940122601 Esterase inhibitor Drugs 0.000 description 2
- 108010058861 Fibrin Fibrinogen Degradation Products Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010048748 Graft loss Diseases 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 102000002261 High-Molecular-Weight Kininogen Human genes 0.000 description 2
- 108010000487 High-Molecular-Weight Kininogen Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000012479 Serine Proteases Human genes 0.000 description 2
- 108010022999 Serine Proteases Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229940088950 c1 esterase inhibitor (human) Drugs 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000004074 complement inhibitor Substances 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000002329 esterase inhibitor Substances 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000000208 fibrin degradation product Substances 0.000 description 2
- 206010061989 glomerulosclerosis Diseases 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000003001 serine protease inhibitor Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000008227 sterile water for injection Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 description 2
- -1 without limitation Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 108010028774 Complement C1 Proteins 0.000 description 1
- 102100025406 Complement C1s subcomponent Human genes 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 101710192606 Latent membrane protein 2 Proteins 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102100026061 Mannan-binding lectin serine protease 1 Human genes 0.000 description 1
- 108010042484 Mannose-Binding Protein-Associated Serine Proteases Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 101710132632 Protein C4 Proteins 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010049771 Shock haemorrhagic Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 101710109576 Terminal protein Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010060872 Transplant failure Diseases 0.000 description 1
- 239000012963 UV stabilizer Substances 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 208000037908 antibody-mediated disorder Diseases 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000037058 blood plasma level Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 229940075234 cytogam Drugs 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 229940069042 gamunex Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000000585 glomerular basement membrane Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 108091006086 inhibitor proteins Proteins 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000008011 inorganic excipient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000001806 memory b lymphocyte Anatomy 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000031978 negative regulation of complement activation Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 231100001079 no serious adverse effect Toxicity 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000008012 organic excipient Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000009118 salvage therapy Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010911 splenectomy Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361907550P | 2013-11-22 | 2013-11-22 | |
| US201462029086P | 2014-07-25 | 2014-07-25 | |
| PCT/US2014/066784 WO2015077543A1 (en) | 2013-11-22 | 2014-11-21 | Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2708655T3 true ES2708655T3 (es) | 2019-04-10 |
Family
ID=52016153
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14809567T Active ES2708655T3 (es) | 2013-11-22 | 2014-11-21 | Métodos para tratar el rechazo mediado por anticuerpos en pacientes con trasplante de órganos con el inhibidor de la c1-esterasa |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US9895428B2 (enExample) |
| EP (3) | EP4162947A1 (enExample) |
| JP (5) | JP6431912B2 (enExample) |
| KR (2) | KR102312817B1 (enExample) |
| CN (2) | CN111388655A (enExample) |
| AU (2) | AU2014352846B2 (enExample) |
| BR (1) | BR112016011499A2 (enExample) |
| CA (1) | CA2930964A1 (enExample) |
| CY (1) | CY1121298T1 (enExample) |
| DK (1) | DK3071219T3 (enExample) |
| ES (1) | ES2708655T3 (enExample) |
| HR (1) | HRP20190184T1 (enExample) |
| HU (1) | HUE041809T2 (enExample) |
| LT (1) | LT3071219T (enExample) |
| ME (1) | ME03318B (enExample) |
| MX (2) | MX378834B (enExample) |
| NZ (2) | NZ719724A (enExample) |
| PL (1) | PL3071219T3 (enExample) |
| PT (1) | PT3071219T (enExample) |
| RS (1) | RS58343B1 (enExample) |
| SG (1) | SG10201804326SA (enExample) |
| SI (1) | SI3071219T1 (enExample) |
| SM (1) | SMT201900042T1 (enExample) |
| WO (1) | WO2015077543A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3071219T3 (pl) * | 2013-11-22 | 2019-04-30 | Shire Viropharma Inc | Sposoby leczenia zależnego od przeciwciała odrzucenia przeszczepu narządu u pacjentów za pomocą inhibitora esterazy c1 |
| CA3075686A1 (en) * | 2017-09-15 | 2019-03-21 | Cedars-Sinai Medical Center | Methods for improving organ function in organ transplant patients |
| WO2019166572A1 (en) * | 2018-02-28 | 2019-09-06 | Pharming Intellectual Property B.V. | Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor |
| EP3897718A4 (en) * | 2018-12-20 | 2022-09-14 | Cedars-Sinai Medical Center | CLAZAKIZUMAB FOR THE TREATMENT OF CHRONIC ANTIBODY-MEDIATED REJECTION OF ORGAN TRANSPLANT |
| WO2021026507A1 (en) * | 2019-08-08 | 2021-02-11 | Cedars-Sinai Medical Center | Methods of improving organ function |
| EP3895726A1 (en) | 2020-04-17 | 2021-10-20 | Pharming Intellectual Property BV | Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress |
| CN116568327A (zh) * | 2020-11-20 | 2023-08-08 | 德国杰特贝林生物制品有限公司 | 治疗抗体介导的排斥反应的方法 |
| CN113035369B (zh) * | 2021-03-10 | 2021-12-03 | 浙江大学 | 一种肾移植抗感染药物剂量预测模型的构建方法 |
| US20240342258A1 (en) | 2021-07-09 | 2024-10-17 | Pharming Intellectual Property B.V. | Using c1 esterase inhibitor to treat viral infection-related symptoms |
| WO2024152030A1 (en) * | 2023-01-13 | 2024-07-18 | The Uab Research Foundation | Crossmatching for porcine xenotransplantation |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4212278B2 (ja) * | 2001-03-01 | 2009-01-21 | 日本たばこ産業株式会社 | 移植片拒絶反応抑制剤 |
| DE10112617A1 (de) | 2001-03-14 | 2002-10-02 | Aventis Behring Gmbh | Verwendung eines C1-Esterase-Inhibitors zur Verhinderung oder Verzögerung der Abstoßung von Xenotransplantaten in Säugetieren |
| ES2516690T5 (es) | 2005-06-07 | 2017-11-21 | The Regents Of The University Of Colorado, A Body Corporate | Inhibidores de la actividad de serina proteasa y su uso en métodos y composiciones para el tratamiento de rechazo de injertos y promoción de supervivencia de injertos |
| EP1988882B1 (en) * | 2006-03-02 | 2014-12-17 | Alexion Pharmaceuticals, Inc. | Prolongation of survival of an allograft by inhibiting complement activity |
| EP2758076B1 (en) | 2011-09-24 | 2018-12-12 | CSL Behring GmbH | Combination therapy using immunoglobulin and c1-inhibitor |
| US10286047B2 (en) * | 2013-03-08 | 2019-05-14 | Csl Behring Gmbh | Treatment and prevention of remote ischemia-reperfusion injury |
| DE202014011208U1 (de) | 2013-03-15 | 2018-08-23 | Shire Viropharma Incorporated | C1-INH Zusammensetzungen für die Vorbeugung und Behandlung von Störungen, die mit C1-Esterasehemmer-Defizienz assoziiert sind |
| PL3071219T3 (pl) | 2013-11-22 | 2019-04-30 | Shire Viropharma Inc | Sposoby leczenia zależnego od przeciwciała odrzucenia przeszczepu narządu u pacjentów za pomocą inhibitora esterazy c1 |
-
2014
- 2014-11-21 PL PL14809567T patent/PL3071219T3/pl unknown
- 2014-11-21 MX MX2016006656A patent/MX378834B/es unknown
- 2014-11-21 SI SI201431066T patent/SI3071219T1/sl unknown
- 2014-11-21 ES ES14809567T patent/ES2708655T3/es active Active
- 2014-11-21 CN CN202010018792.0A patent/CN111388655A/zh active Pending
- 2014-11-21 NZ NZ719724A patent/NZ719724A/en unknown
- 2014-11-21 NZ NZ759187A patent/NZ759187A/en unknown
- 2014-11-21 AU AU2014352846A patent/AU2014352846B2/en active Active
- 2014-11-21 WO PCT/US2014/066784 patent/WO2015077543A1/en not_active Ceased
- 2014-11-21 EP EP22188379.6A patent/EP4162947A1/en active Pending
- 2014-11-21 ME MEP-2019-31A patent/ME03318B/me unknown
- 2014-11-21 RS RS20190148A patent/RS58343B1/sr unknown
- 2014-11-21 JP JP2016532586A patent/JP6431912B2/ja active Active
- 2014-11-21 DK DK14809567.2T patent/DK3071219T3/en active
- 2014-11-21 CN CN201480063697.5A patent/CN105744949A/zh active Pending
- 2014-11-21 EP EP14809567.2A patent/EP3071219B1/en not_active Revoked
- 2014-11-21 HR HRP20190184TT patent/HRP20190184T1/hr unknown
- 2014-11-21 KR KR1020167013463A patent/KR102312817B1/ko active Active
- 2014-11-21 BR BR112016011499-0A patent/BR112016011499A2/pt not_active Application Discontinuation
- 2014-11-21 HU HUE14809567A patent/HUE041809T2/hu unknown
- 2014-11-21 CA CA2930964A patent/CA2930964A1/en not_active Abandoned
- 2014-11-21 EP EP18205998.0A patent/EP3494988B1/en active Active
- 2014-11-21 PT PT14809567T patent/PT3071219T/pt unknown
- 2014-11-21 LT LTEP14809567.2T patent/LT3071219T/lt unknown
- 2014-11-21 SG SG10201804326SA patent/SG10201804326SA/en unknown
- 2014-11-21 US US14/550,075 patent/US9895428B2/en active Active
- 2014-11-21 KR KR1020217032180A patent/KR102384814B1/ko active Active
- 2014-11-21 SM SM20190042T patent/SMT201900042T1/it unknown
-
2016
- 2016-05-20 MX MX2021000332A patent/MX2021000332A/es unknown
-
2017
- 2017-12-18 US US15/844,850 patent/US20180104319A1/en not_active Abandoned
-
2018
- 2018-10-15 JP JP2018194167A patent/JP6620206B2/ja active Active
- 2018-11-15 JP JP2018214342A patent/JP2019023233A/ja not_active Withdrawn
-
2019
- 2019-01-29 CY CY20191100119T patent/CY1121298T1/el unknown
-
2020
- 2020-01-02 AU AU2020200015A patent/AU2020200015B2/en active Active
- 2020-08-03 US US16/983,998 patent/US20200360495A1/en not_active Abandoned
-
2021
- 2021-01-29 JP JP2021012833A patent/JP2021063141A/ja not_active Withdrawn
-
2022
- 2022-10-11 JP JP2022163044A patent/JP2022179637A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2708655T3 (es) | Métodos para tratar el rechazo mediado por anticuerpos en pacientes con trasplante de órganos con el inhibidor de la c1-esterasa | |
| EA023344B1 (ru) | Способ лечения или предотвращения нейтропении или лейкопении или снижения частоты возникновения инфекции, проявляющейся фебрильной нейтропенией | |
| ES2216516T3 (es) | Inmunorregulador. | |
| Emlen et al. | Therapeutic complement inhibition: new developments | |
| ES2913946T3 (es) | Péptido y su uso en el tratamiento de trastornos inflamatorios | |
| JP2018509398A (ja) | Ｃ１エステラーゼ阻害剤の医薬製剤 | |
| HK40091830A (en) | Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor | |
| HK40008415B (en) | Treatment of antibody-mediated rejection in organ transplant patients with c1- esterase inhibitor | |
| ES2369522T3 (es) | Uso de un inhibidor c1 para la prevención de lesiones por isquemia-reperfusión. | |
| HK40008415A (en) | Treatment of antibody-mediated rejection in organ transplant patients with c1- esterase inhibitor | |
| HK1229241A1 (en) | Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor | |
| HK1229241B (en) | Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor | |
| HK1240072A1 (en) | Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor | |
| US20130045924A1 (en) | Methods of reducing hypoxic stress in a mammal by administering soluble p-selectin | |
| Lauer et al. | PF Zipfel () Department of Infection Biology, Leibniz Institute for Natural Product Research and Infection Biology, Beutenbergstrasse 11a, 07745 Jena, Germany Friedrich Schiller University, Fürstengraben 1, 07743 Jena, Germany email: peter. zipfel@ hki-jena. de | |
| Woodell | The Alternative Complement Pathway Mediates Chronic Smoke-Induced Functional and Morphological Ocular Injury | |
| US20050059582A1 (en) | Use of soluble P-selectin and anthrax lethal toxin |